Nov 16 2011
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis' Lm-LLO based immunotherapies from the University of Pennsylvania. This intellectual property resulted from research conducted in Dr. Yvonne Paterson's laboratory that demonstrated ISG15 was an effective immunological target for the treatment of breast cancer in animal models.
"Targeting ISG15 may represent a therapeutic approach suitable for a population of patients with advanced breast cancer for whom few approved treatments currently exist. The research conducted by Dr. Paterson and colleagues, as well as research conducted at other institutions, suggests that this antigen may have utility in treating other tumor types as well. ISG15 is Advaxis' first proprietary antigen," said Dr. John Rothman, Executive Vice President, Science & Operations.
3D-printed model created to mimic cancer metastasis